Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 315

1.

Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD.

Vijayasaratha K, Stockley RA.

Int J Chron Obstruct Pulmon Dis. 2012;7:789-96. doi: 10.2147/COPD.S31797. Epub 2012 Nov 27.

2.

Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency.

Omachi TA, Eisner MD, Rames A, Markovtsova L, Blanc PD.

Respir Res. 2011 Mar 23;12:35. doi: 10.1186/1465-9921-12-35.

3.

Correlation between annual change in health status and computer tomography derived lung density in subjects with alpha1-antitrypsin deficiency.

Stolk J, Ng WH, Bakker ME, Reiber JH, Rabe KF, Putter H, Stoel BC.

Thorax. 2003 Dec;58(12):1027-30. Erratum in: Thorax. 2004 Feb;59(2):179.

4.

A score to predict short-term risk of COPD exacerbations (SCOPEX).

Make BJ, Eriksson G, Calverley PM, Jenkins CR, Postma DS, Peterson S, Östlund O, Anzueto A.

Int J Chron Obstruct Pulmon Dis. 2015 Jan 27;10:201-9. doi: 10.2147/COPD.S69589. eCollection 2015.

5.

Exacerbation frequency and course of COPD.

Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP.

Int J Chron Obstruct Pulmon Dis. 2012;7:653-61. doi: 10.2147/COPD.S34186. Epub 2012 Sep 21.

6.

Rate of progression of lung function impairment in alpha1-antitrypsin deficiency.

Dawkins PA, Dawkins CL, Wood AM, Nightingale PG, Stockley JA, Stockley RA.

Eur Respir J. 2009 Jun;33(6):1338-44. doi: 10.1183/09031936.00061208. Epub 2009 Jan 22.

7.
8.

Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes.

Anzueto A, Leimer I, Kesten S.

Int J Chron Obstruct Pulmon Dis. 2009;4:245-51. Epub 2009 Jul 20.

9.

Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography.

Subramanian DR, Jenkins L, Edgar R, Quraishi N, Stockley RA, Parr DG.

Am J Respir Crit Care Med. 2012 Dec 1;186(11):1125-32. doi: 10.1164/rccm.201201-0051OC. Epub 2012 Jul 26.

PMID:
22837375
10.

Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy.

Barros-Tizón JC, Torres ML, Blanco I, Martínez MT; Investigators of the rEXA study group.

Ther Adv Respir Dis. 2012 Apr;6(2):67-78. doi: 10.1177/1753465812438387. Epub 2012 Feb 21.

PMID:
22354900
11.

Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency.

Demeo DL, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard S, Burchard E, Stocks JM, Stoller JK, Strange C, Turino GM, Campbell EJ, Silverman EK.

Thorax. 2007 Sep;62(9):806-13. Epub 2007 Mar 27.

12.

Emphysematous phenotype is an independent predictor for frequent exacerbation of COPD.

Oh YM, Sheen SS, Park JH, Jin UR, Yoo JW, Seo JB, Yoo KH, Lee JH, Kim TH, Lim SY, Yoon HI, Lee JS, Lee SD.

Int J Tuberc Lung Dis. 2014 Dec;18(12):1407-14. doi: 10.5588/ijtld.14.0205.

PMID:
25517804
13.

Exacerbations of chronic obstructive pulmonary disease.

Wedzicha JA, Donaldson GC.

Respir Care. 2003 Dec;48(12):1204-13; discussion 1213-5. Review.

14.

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency.

Parr DG, Dirksen A, Piitulainen E, Deng C, Wencker M, Stockley RA.

Respir Res. 2009 Aug 13;10:75. doi: 10.1186/1465-9921-10-75.

15.

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA.

Thorax. 2002 Oct;57(10):847-52. Erratum in: Thorax. 2008 Aug;63(8):753.

16.

Response patterns to bronchodilator and quantitative computed tomography in chronic obstructive pulmonary disease.

Lee JS, Huh JW, Chae EJ, Seo JB, Ra SW, Lee JH, Kim EK, Lee YK, Kim TH, Kim WJ, Lee JH, Lee SM, Lee S, Lim SY, Shin TR, Yoon HI, Sheen SS, Oh YM, Lee SD.

Clin Physiol Funct Imaging. 2012 Jan;32(1):12-8. doi: 10.1111/j.1475-097X.2011.01046.x. Epub 2011 Aug 18.

PMID:
22152074
17.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
18.

Association between lung function and exacerbation frequency in patients with COPD.

Hoogendoorn M, Feenstra TL, Hoogenveen RT, Al M, Mölken MR.

Int J Chron Obstruct Pulmon Dis. 2010 Dec 9;5:435-44. doi: 10.2147/COPD.S13826. Review.

19.
20.

Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials.

Cooper CB, Anzueto A, Decramer M, Celli B, Tashkin DP, Leimer I, Kesten S.

Int J Chron Obstruct Pulmon Dis. 2011;6:269-75. doi: 10.2147/COPD.S17864. Epub 2011 May 9.

Items per page

Supplemental Content

Write to the Help Desk